Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | LGMN | Q99538 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16824933 | 0.85 | MAPT (0.43) | MAPTSMN1; SMN2GAANPC1ALDH1A1 | |
| SCHEMBL17536983 | 0.85 | SMN1; SMN2 (0.50) | MAPTSMN1; SMN2GAANPC1ALDH1A1 | |
| SCHEMBL16824825 | 0.81 | ALDH1A1 (0.54) | MAPTSMN1; SMN2NPC1ALDH1A1LMNA | |
| SCHEMBL24630249 | 0.81 | MAPT (0.61) | MAPTSMN1; SMN2GAANPC1ALDH1A1 | |
| SCHEMBL29769230 | 0.81 | MAPT (0.61) | MAPTSMN1; SMN2GAANPC1ALDH1A1 | |
| SCHEMBL16824848 | 0.79 | MAPT (0.58) | MAPTSMN1; SMN2GAANPC1ALDH1A1 | |
| SCHEMBL29949140 | 0.79 | MAPT (0.58) | MAPTSMN1; SMN2GAANPC1ALDH1A1 | |
| SCHEMBL13244136 | 0.77 | SMN1; SMN2 (0.44) | MAPTSMN1; SMN2GAANPC1ALDH1A1 | |
| SCHEMBL188672 | 0.76 | MAPT (0.61) | MAPTSMN1; SMN2GAANPC1ALDH1A1 | |
| SCHEMBL17536985 | 0.75 | SMN1; SMN2 (0.45) | MAPTSMN1; SMN2GAANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083625-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | Almac Discovery Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092431-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | MAPT 3728/4885SMN1; SMN2 4422/4885GAA 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.